Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical pr ...

Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...

Prescient Therapeutics (ASX: PTX) has received fast-track designation from the US Food and Drug Administration for lead ...

Tumors develop when cells in the body grow uncontrollably ... However, tumors in dogs are most common in the skin, heart, and spleen. Hemangiosarcomas are highly invasive and can be deadly. They are ...

The current first-line treatment for peripheral T-cell lymphoma (PTCL) has a typically poor prognosis. Developing a new regimen is urgently needed. This phase I study evaluated the maximum tolerated ...

Nearly one million people worldwide are plagued annually by cutaneous leishmaniasis, a devastating skin infection caused ... UMD Professor of Cell Biology and Molecular Genetics Najib El-Sayed ...

Brian Hess, director of CAR T cell therapy and lymphoma at Hollings. Those patients typically had a "very, very poor prognosis" where the chances of successful treatment were around 5 percent to ...

More information: Yago Nieto et al, Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial, Nature Medicine (2025). DOI: 10.1038/s41591-025 ...

This trial enrolled 37 adult patients with CD30-positive Hodgkin lymphoma and five with T-cell lymphoma. Patients were heavily pretreated and were refractory to brentuximab vedotin and anti-PD1 ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell therapies for solid tumors. The recent American Society of Clinical ...